Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: A 26-week, randomised, treat-to-target trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kaneko, Shizuka | - |
dc.contributor.author | Chow, Francis | - |
dc.contributor.author | Choi, Dong Seop | - |
dc.contributor.author | Taneda, Shinji | - |
dc.contributor.author | Hirao, Koichi | - |
dc.contributor.author | Park, Yongsoo | - |
dc.contributor.author | Andersen, Thomas Hasseriis | - |
dc.contributor.author | Gall, Mari-Anne | - |
dc.contributor.author | Christiansen, Jens Sandahl | - |
dc.date.accessioned | 2021-09-04T20:25:08Z | - |
dc.date.available | 2021-09-04T20:25:08Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2015-01 | - |
dc.identifier.issn | 0168-8227 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/94752 | - |
dc.description.abstract | Aims: Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of IDeg and IAsp. This pan-Asian, 26-week trial investigated efficacy and safety of IDegAsp vs biphasic insulin aspart 30 (BIAsp 30) in Asian adults with type 2 diabetes (T2DM), inadequately controlled on once-or twice-daily (BID) basal, premixed or self-mixed insulin. Methods: Participants (mean age 59.8 years, HbA1c 8.4%, FPG 7.9 mmol/L, BMI 25.4 kg/m2) were randomised 2: 1 to BID IDegAsp (n = 282) or BIAsp 30 (n = 142) and continued existing metformin treatment. Insulins were administered with breakfast and main evening meal, titrated to a pre-breakfast and pre-main evening meal self-measured plasma glucose target of 4-5 mmol/L. Results: IDegAsp achieved the primary endpoint of non-inferiority to BIAsp 30 for mean change in HbA1c (estimated treatment difference [ETD] IDegAsp-BIAsp 30: 0.05% points [95% CI +/- 0.10; 0.20]). IDegAsp was superior in lowering fasting plasma glucose (FPG) (ETD +/- 1.06 mmol/L, 95% CI +/- 1.43; +/- 0.70, p < 0.001), and resulted in a lower final mean daily insulin dose (0.79 U/kg vs 0.99 U/kg, estimated rate ratio [RR] 0.79, 95% CI 0.73; 0.85, p < 0.0001).Rates of overall confirmed and severe hypoglycaemia were similar between treatments, while rate of nocturnal confirmed hypoglycaemia was numerically (p = ns) lower with IDegAsp. During the maintenance period there was a trend (p = ns) towards lower hypoglycaemia rates for IDegAsp. Conclusion: In Asian adults with T2DM, IDegAsp BID effectively improves long-term glycaemic control, and compared to BIAsp 30, provides superior reductions in FPG with a lower dose, and numerically less nocturnal hypoglycaemia. (C) 2014 The Authors. Published by Elsevier Ireland Ltd. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER IRELAND LTD | - |
dc.subject | GLYCEMIC CONTROL | - |
dc.subject | STEADY-STATE | - |
dc.subject | GLARGINE | - |
dc.subject | INDIVIDUALS | - |
dc.subject | EFFICACY | - |
dc.subject | PEOPLE | - |
dc.subject | IMPACT | - |
dc.subject | SAFETY | - |
dc.title | Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: A 26-week, randomised, treat-to-target trial | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Dong Seop | - |
dc.identifier.doi | 10.1016/j.diabres.2014.09.026 | - |
dc.identifier.scopusid | 2-s2.0-84922809906 | - |
dc.identifier.wosid | 000348045800019 | - |
dc.identifier.bibliographicCitation | DIABETES RESEARCH AND CLINICAL PRACTICE, v.107, no.1, pp.139 - 147 | - |
dc.relation.isPartOf | DIABETES RESEARCH AND CLINICAL PRACTICE | - |
dc.citation.title | DIABETES RESEARCH AND CLINICAL PRACTICE | - |
dc.citation.volume | 107 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 139 | - |
dc.citation.endPage | 147 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Endocrinology & Metabolism | - |
dc.subject.keywordPlus | GLYCEMIC CONTROL | - |
dc.subject.keywordPlus | STEADY-STATE | - |
dc.subject.keywordPlus | GLARGINE | - |
dc.subject.keywordPlus | INDIVIDUALS | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | PEOPLE | - |
dc.subject.keywordPlus | IMPACT | - |
dc.subject.keywordPlus | SAFETY | - |
dc.subject.keywordAuthor | Insulin degludec | - |
dc.subject.keywordAuthor | Insulin aspart | - |
dc.subject.keywordAuthor | Type 2 diabetes | - |
dc.subject.keywordAuthor | HbA1c | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.